Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Travoprost (Primary) ; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Glaukos Corporation
- 14 Jan 2025 Results published in the Glaukos Corporation media release
- 14 Jan 2025 According to Glaukos Media Release, company announced positive follow-up analysis of this trial demonstrating excellent tolerability and a favorable safety profile of iDose TR (travoprost intracameral implant) 75 mcg
- 28 Nov 2024 Status changed from active, no longer recruiting to completed.